GlassScriptPhysician profile
Vladimir Liberman
NPI 1780944876
$7,931.86
in general payments reported to CMS, 2019-2025
33 companies · $2,761 in 2025
The $2,761 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $240 · 2021: $332 · 2022: $512 · 2023: $1,449 · 2024: $1,860 · 2025: $2,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683 · Travel and Lodging: $311 · Education: $75.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.82 |
| Travel and Lodging | $310.96 |
| Education | $75.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,520.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,265.00 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $619.62 | 2019-2025 | Krystexxa, Repatha, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $500.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.03 | 2021-2025 | Jardiance |
| Vifor Pharma, INC. | $434.07 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $422.07 | 2019-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $289.82 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $268.88 | 2020-2025 | Acthar |
| Allergan, INC. | $249.73 | 2019-2020 | |
| Novo Nordisk INC | $227.72 | 2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $208.03 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Aurinia Pharma U.S., INC. | $190.20 | 2023-2025 | Lupkynis |
| Travere Therapeutics, INC. | $167.20 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $134.87 | 2019-2025 | Velphoro, Velphoro, Korsuva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $121.65 | 2019-2025 | Rayaldee |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.98 | 2024-2025 | |
| Nxstage Medical, INC. | $101.89 | 2024 | |
| Renalytix Ai, INC. | $87.80 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Calliditas Therapeutics US INC. | $76.44 | 2023-2024 | Tarpeyo |
| Akebia Therapeutics INC | $48.65 | 2019 | |
| Lilly USA, LLC | $39.51 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $37.86 | 2022 | |
| Pfizer INC. | $34.44 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.98 | 2019-2024 | Gattex |
| Scpharmaceuticals INC. | $28.63 | 2025 | |
| Mallinckrodt Enterprises LLC | $28.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $25.30 | 2025 | Tryvio |
| Ani Pharmaceuticals, INC. | $22.27 | 2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $18.39 | 2023 | Krystexxa |
| Shire North American Group INC | $16.22 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Liberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.